Wuxi Biologics readies Hong Kong relisting

Wuxi PharmaTech is looking to relist its biologic arm in Hong Kong after the group was taken private through a management buyout in late 2015.

Wuxi Biologics readies Hong Kong relisting

Shanghai-headquartered biopharmaceutical firm Wuxi PharmaTech has taken the first step to relist its biologics unit in Hong Kong after filing a listing application with the city’s stock exchange this week.

The plan to list Wuxi Biologics emerged little more than a year after China’s largest contract research organisation delisted from the New York Stock Exchange in December 2015, following a $3.3 billion buyout by a consortium that included company founder...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition


  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...